Stay updated with breaking news from Timothy Yap. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two early-phase clinical trials presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center demonstrate promising responses and safety profiles in heavily pretreated patients with advanced solid tumors.
Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for investigating saruparib in advanced solid tumors, such as prostate cancer with genetic mutations.
Tony Cummings reports on singer, songwriter, pop artist, worship leader, soul singer, rapper . oh, and did we mention family man, BRANAN MURPHY
Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.
/PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases,...